ArticleFrontiers in veterinary science2025
Case Report: Management of a delayed type III hypersensitivity reaction with acute kidney injury in a dog after administration of human serum albumin with immunoadsorption.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A six-year-old, intact male German Shepherd, weighing 43 kg, was presented with generalized edema formation and acute kidney injury due to a suspected delayed type III hypersensitivity reaction and vasculitis 2 weeks after the administration of human serum albumin (HSA). At presentation, the patient had a moderately reduced general condition, a heart rate of 96/min, rectal temperature of 37.0 °C, generalized edema, hematoma and petechiae on all limbs and the abdomen, and scleral hemorrhage. The initial blood work showed a moderate anemia, a severe azotemia, and a moderate hypoalbuminemia. Marked proteinuria with a urine protein-creatinine ratio (UPC) of 6.26 was present. The presence of anti-HSA antibodies was proven with an in-house ELISA. For treatment, immunoadsorption (IA) was performed with the TheraSorb® Ig Omni 1 adsorber, which was integrated in the LIFE 21® apheresis unit. Due to severe azotemia, an intermittent hemodialysis treatment with the dialysis platform Fresenius 4008 was performed after IA. Both treatments were repeated on the following day. A total plasma volume of 1.9 liters and 3.7 liters, respectively, was processed with IA. On the following days, creatinine concentration declined and the patient improved significantly. The patient was discharged after 10 days. UPC decreased to 0.82 and edema completely resolved. Two weeks after discharge, Creatinine, UPC and albumin were in the reference range. IA might be an additional therapeutic option for dogs with severe acute kidney injury due to a suspected delayed type III hypersensitivity reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.